Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis". by Popa, C. & Netea, M.G.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/69511
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Letter by Popa and Netea Regarding
Article, “Angiotensin-Converting Enzyme
Inhibition Improves Vascular Function in
Rheumatoid Arthritis”
To the Editor:
We read with great interest the article by Flammer et al,1 in which
the authors investigated the effects of ramipril on endothelial
function during rheumatoid arthritis. They concluded that ramipril is
able to significantly improve endothelial function as early as 8 weeks
after daily therapy has been initiated. Therefore, their findings may
have a significant impact on our attempts to diminish the increased
cardiovascular risk of these patients and to improve their lifespan.
However, several important aspects should be considered in the
interpretation of these results. First, the concentrations of tumor
necrosis factor (TNF) detected by the authors are very low but are in
the range of the minimum detectable dose of TNF stated by the
manufacturer.2 This may cause an important bias and therefore call
into question the relation described by the authors between flow-
mediated dilation and circulating levels of this cytokine. Second, 3 of
the 11 patients included received anti-TNF agents. We have previ-
ously indicated that ELISA is unable to give a reliable TNF plasma
concentration in this particular situation because it cannot distinguish
between free and anti-TNF–bound TNF.3 Third, therapeutic TNF
neutralization on its own also is able to improve endothelial
function,4 adding to the complexity of the authors’ findings. We
therefore wonder if the authors’ conclusions would be the same if
these patients were excluded from the study analysis.
We believe that the authors’ findings are biased by several
methodological issues that cast a shadow on the impact of their
conclusions. However, we also believe that further exploration of
angiotensin-converting enzyme inhibitory strategies in rheumatoid
arthritis is of extreme importance to lessen the increased burden of
cardiovascular disease characterizing these patients.
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